AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
188.01
-5.02 (-2.60%)
At close: Feb 9, 2026, 4:00 PM EST
189.00
+0.99 (0.53%)
After-hours: Feb 9, 2026, 7:59 PM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
$58.13B
Revenue Growth
+13.52%
P/S Ratio
5.07
Revenue / Employee
$625,694
Employees
92,900
Market Cap
294.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 94.19B |
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| Novartis AG | 56.67B |
| Sanofi | 54.85B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
AZN News
- 37 minutes ago - AstraZeneca Forecasts Continued Growth on Pipeline Strength - WSJ
- 47 minutes ago - AstraZeneca profit climbs on cancer and heart drug demand - Market Watch
- 1 hour ago - Drugmaker AstraZeneca forecasts sales and profit growth in 2026 - Reuters
- 1 day ago - Oakmark International Strategy Q4 2025 New Investments And Divestments - Seeking Alpha
- 7 days ago - AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA - WSJ
- 7 days ago - US FDA rejects AstraZeneca's easier-to-use version of lupus therapy - Reuters
- 7 days ago - AstraZeneca begins trading on the New York Stock Exchange - Business Wire
- 9 days ago - AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation - CNBC